Using blood tests to improve ovarian cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the use of circulating tumor DNA (ctDNA) in women with suspected ovarian cancer to enhance diagnostic accuracy. The study aims to evaluate the effectiveness of ctDNA alone and in combination with imaging techniques and CA 125 levels for distinguishing between benign and malignant ovarian masses before surgery. Blood and tissue samples will be collected from participants to analyze disease progression and biology, ultimately leading to the development of a more effective diagnostic algorithm.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Suspected ovarian neoplasm
* Informed consent

Exclusion Criteria:

* Inability to give informed consent
* Previous ovarian cancer diagnosis

Where it's running

• Department of Gynaecology and Obstetrics, Aarhus University Hospital
  Aarhus, Denmark Recruiting

Study contacts

• Principal investigator: Ina Marie Dueholm Hjorth, MD — University of Aarhus
• Study coordinator: Ina Marie Dueholm Hjorth, MD
• Email: imhjorth@gmail.com
• Phone: +4526192456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN

  This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.

  Recruiting at 12 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 11 other locations · NCT06051695

• Improving diagnosis of ovarian cancer using imaging methods

  This study is trying to improve how doctors diagnose ovarian cancer by using different imaging techniques and descriptions to better tell the difference between harmless and harmful growths in the ovaries.

  Recruiting University of Aarhus · Aarhus · NCT05842629

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Ovarian Reserve After Cystectomy for Endometriotic vs. Non-Endometriotic Cysts

  This study tests how laparoscopic removal of ovarian cysts affects ovarian reserve in women with endometriotic cysts compared to benign/non-endometriotic cysts.

  Recruiting Benha University · Banhā, Qalyubia Governorate · NCT07686783

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.